Nucleic Acid Standards for Biosecurity Act
- Bill Number
- H.R. 3029
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Science, Technology, Communications
- Status
- Introduced
- Latest Action
- 2025-04-29: Ordered to be Reported by Voice Vote.
- Last Updated
- 2025-06-24T20:20:18Z
AI-Generated Summary
Purpose
The Nucleic Acid Standards for Biosecurity Act (H.R. 3029) aims to enhance biosecurity in the field of synthetic biology by promoting research, standards, and best practices for screening nucleic acids— the building blocks of DNA and RNA— during synthesis processes. This helps prevent potential misuse, such as creating harmful biological agents, while supporting innovation in engineering biology and biomanufacturing.
Key Provisions
- Amendments to Existing Law: Updates Section 10221 of the Research and Development, Competition, and Innovation Act (part of the CHIPS and Science Act of 2022) to include new requirements for the National Institute of Standards and Technology (NIST).
- Risk Management Standards: Adds guidelines and technical standards for managing risks in engineering biology and biomanufacturing, including those related to artificial intelligence (AI) use.
- Nucleic Acid Screening Research: Directs the NIST Director, in consultation with relevant federal agencies, to conduct measurement research on biosecurity for nucleic acid synthesis. This includes:
- Testing to improve the accuracy and reliability of screening tools.
- Best practices for security controls and managing databases of concerning genetic sequences.
- Guidance on secure implementation of screening.
- Standards for assessing compliance (conformity assessment) and evaluating overall effectiveness.
- Stakeholder Consortium: NIST must convene a group including industry, universities, nonprofits, and customers to:
- Develop and update priorities and best practices for screening synthetic nucleic acids.
- Create roadmaps to guide the research activities.
- Reporting Requirement: NIST must submit a report to specified congressional committees (Senate Commerce, Science, and Transportation; House Science, Space, and Technology) within 18 months of the consortium's first meeting, summarizing its findings.
- Funding: Authorizes $5 million annually for fiscal years 2026 through 2030, drawn from NIST's budget for scientific and technical research.
Significant Changes to Existing Law
- Expands the scope of NIST's responsibilities under the Research and Development, Competition, and Innovation Act by inserting a new subsection focused specifically on nucleic acid synthesis screening.
- Introduces a dedicated consortium mechanism and reporting obligation, which were not previously required.
- Incorporates AI-related risks into broader risk management standards for biomanufacturing, building on existing provisions for innovation and competition.
Potential Impacts
- Government Agencies: NIST will lead new research and coordination efforts, potentially increasing workload and collaboration with agencies like those in health, defense, and homeland security. This could strengthen federal biosecurity frameworks without creating new regulatory burdens.
- Citizens and Industry: Enhances safety in biotech by reducing risks from synthetic biology, benefiting researchers, manufacturers, and the public through more reliable screening tools. It may indirectly support economic growth in the bioeconomy by fostering secure innovation.
- International Relations: Could position the U.S. as a leader in global biosecurity standards, influencing international norms for nucleic acid synthesis and potentially aiding diplomatic efforts on biological threats, though it focuses domestically.
Main Stakeholders Affected
- Federal Agencies: Primarily NIST, with input from agencies involved in science, technology, and security (e.g., Department of Health and Human Services, Department of Defense).
- Industry and Businesses: Companies in synthetic biology, biomanufacturing, and nucleic acid synthesis providers, who will participate in the consortium and adopt new standards.
- Academic and Nonprofit Institutions: Universities and research organizations focused on engineering biology, contributing to and benefiting from updated best practices.
- Customers and End-Users: Entities procuring synthetic nucleic acids, such as pharmaceutical firms or labs, who will use improved screening for secure operations.
Notable Legal, Constitutional, or Political Implications
- Legal: Establishes voluntary standards and research without mandating new regulations, avoiding direct enforcement but enabling future policy through consensus-building. It builds on existing authorizations under the CHIPS and Science Act, ensuring continuity.
- Constitutional: No apparent conflicts; it aligns with Congress's authority to fund and direct scientific research for public welfare and national security under the Commerce Clause and general welfare provisions.
- Political: Introduced bipartisansely (by Rep. Salinas, D-OR, and Rep. McCormick, R-GA), signaling broad support for biosecurity amid rising concerns over biotech risks like pandemics or bioweapons. The bill's focus on innovation alongside security may appeal across party lines, though funding levels could spark debates on federal spending priorities.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Rep. McCormick, Richard [R-GA-7], Rep. McBride, Sarah [D-DE-At Large], Rep. Riley, Josh [D-NY-19]
Recent Actions
- 2025-04-29: Ordered to be Reported by Voice Vote.
- 2025-04-29: Committee Consideration and Mark-up Session Held
- 2025-04-28: Referred to the House Committee on Science, Space, and Technology.
- 2025-04-28: Introduced in House
- 2025-04-28: Introduced in House
Bill Versions
- Nucleic Acid Standards for Biosecurity Act — issued 2025-04-28 — PDF (4 pages)